EDAP 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third-quarter 2026 HIFU revenue was $9.8 million, up 26% from $7.8 million in the third quarter of 2025, driven by seven Focal One system sales versus six and a 24% increase in Focal One treatment-driven revenue.
- Revenue fell below expectations because three anticipated system sales were delayed by hospital approval processes and, in one instance, bank financing; management said the delays did not indicate weaker demand or competitive pressure.
- The three systems initially expected in the third quarter were forecast to generate revenue in the fourth quarter; management said one sale had already closed and two purchase orders had been signed.
- The worldwide Focal One install base reached 192 systems, including 98 in the U.S. and 94 internationally, after seven capital system sales and one net operating lease placement in the quarter.
- U.S. Focal One procedure volumes grew 32% year over year, compared with 15% growth in the third quarter of 2025.
- Gross margin increased to 51.4% from 46.6%, a 482 basis point increase, primarily due to improved standard system costs and higher average selling prices for Focal One systems and Focalpaks.
- Operating expenses were $12.8 million versus $10.3 million, and operating loss was $7.8 million versus $6.7 million.
- Net loss was $4.5 million, or $0.10 per share, compared with $5.9 million, or $0.16 per share, in the third quarter of 2025.
- Cash and cash equivalents were $56.3 million at the end of the third quarter, compared with $21.5 million at the end of the second quarter, reflecting net proceeds from the August equity offering.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Greetings, and welcome to the FocalTherics Third Quarter 2026 Conference Call. As a reminder, this conference call is being recorded. I would now like to turn the call over to Louisa Smith from Gilmartin Group.
Good afternoon. Thank you for joining us for the FocalTherics Third Quarter 2026 Financial and Operating Results Conference Call. Joining me on today's call are Ryan Rhodes, Chief Executive Officer, and Ken Mobeck, Chief Financial Officer. Before we begin, I would like to remind everyone that management's remarks today may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and involve risks and uncertainties that could cause actual results to differ materially from those anticipated. We direct you to the risk factor section of our most recently filed annual report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission, as well as our other filings with the SEC for a description of factors that may cause such differences.
These statements speak only as of today's date, and we undertake no obligation to update or revise them, except as required by law. Additionally, this call is being recorded and constitutes a public disclosure for purposes of Regulation FD. I would now like to turn the call over to Chief Executive Officer Ryan Rhodes.
Thanks, Louisa, and thank you all for joining us on today's call. This quarter reflected continued execution against the Focal One growth strategy we set forth for 2026, deepening adoption across leading healthcare systems, expanding reimbursement and access, extending Focal One into new clinical indications, and advancing technology innovation. In the third quarter, we reported HIFU revenue of approximately $9.8 million, an increase of 26% over the prior year period. Revenue was below what we had anticipated due to the timing of three system sales, which I will cover in more detail shortly. Across the business, we made meaningful progress on commercial priorities that are driving long-term growth trajectory of Focal One. We also ended the quarter with a strengthened balance sheet following the completion of our public offering in August and are poised to move forward with conviction to deliver on our strategic plan.
We recorded seven Focal One capital system sales globally in the third quarter compared to six in the prior year period. Those sales, along with one net operating lease placement, bring our total worldwide install base to 192 systems, with 98 in the U.S. and 94 internationally, reflecting the continued broadening of our footprint across academic and community hospitals in both established and emerging markets. Our third quarter revenues were adversely affected by deal timing challenges. We anticipated being able to close on three additional Focal One systems. Sales cycles ran longer due to hospital committee approval processes as a result of the third quarter summer seasonality in hospital capital purchasing activity. These delays account entirely for the gap in our revenue expectations for the quarter. Importantly, they do not indicate a lack of demand for Focal One or competitive market dynamics.
Our pipeline remains strong, and we remain focused on the opportunities ahead. Of note, one of our capital sales this quarter included a second system within the Baylor Scott & White Health system placed in Temple, Texas, which reflects the growing desire to expand access to Focal One for their patients following the purchase of their first system. We now have 16 U.S. hospital networks that have invested in two or more Focal One systems. The purchase of additional systems within a hospital network reflects the strong clinical and economic performance they have seen firsthand in their existing Focal One programs. We also completed a sale to MaineHealth Pen Bay Hospital. This marks our entry into the state of Maine and extends the geographic reach of Focal One further into the New England market.
In California, Kaiser Permanente expanded its Focal One program with two new operating leases in Sacramento and San Francisco, bringing the total to four Focal One systems within the large Kaiser integrated hospital delivery network. Building on their existing programs in Los Angeles and San Diego, Kaiser is reinforcing its growing commitment to Focal One as a cornerstone technology across their growing focal therapy programs. Internationally, we continue to accelerate the commercial momentum of Focal One. We completed two system sales in Turkey, bringing our total in the country to three. We also completed an additional sale in Mexico, building on the first Focal One system placed earlier this year as we expand across Latin America. In France, we completed two additional capital sales this quarter, growing further on our existing momentum in Europe. As a reminder, universal coverage of Focal One by the French National Health System became effective on January 1st of this year.
continues to reinforce the business for the capital purchase of Focal One systems across the country. Turning to utilization, U.S. Focal One procedure volumes grew 32% year-over-year, more than double the 15% growth we reported in the third quarter of 2025. This reflects both the growing contribution of established programs, along with new programs added to our install base. These volumes were in line with what we anticipated given the seasonality of the third quarter. On the reimbursement front, we believe the trajectory of the CMS payment continues to provide hospitals and physicians with a clear and predictable Medicare pathway, which supports the economics of investing in Focal One as the foundation of establishing a prostate cancer focal therapy program. We also continue to focus on prostate cancer patients who have failed radiation therapy.
The large prospective multicenter HIFI-2 study published in April of 2026 demonstrates meaningful oncologic control for patients treated with Focal One robotic HIFU after failure of primary radiation as a treatment. We believe this further strengthens the case for broader payer coverage. The National Comprehensive Cancer Network recently upgraded its recommendation for HIFU as a treatment option for this underserved patient population to category 2A. As a result, several commercial payers have since issued coverage policies for HIFU as a salvage treatment. This includes Aetna, Cigna, Humana, United, Highmark, and other regional Blue Cross Blue Shield plans. A number of these policies were issued over the past six to eight months through a combination of strong physician advocacy, updates to the NCCN guidelines, and our active engagement with these large commercial plans. We continue to invest in building awareness of Focal One across the global surgeon community.
In September, during Prostate Cancer Awareness Month, we partnered with the Chicago Urological Society on a sold-out physician symposium dedicated to use of Focal One robotic HIFU. This event brought together 70 physicians from 35 institutions across 14 states who were interested in adding Focal One to their clinical practice. Additionally, we were active at the Focal Therapy Society annual meeting, the FOCAL+ meeting in San Diego, and the large DGU Congress of the German Society of Urology held in Düsseldorf, Germany. These scientific forums continue to play a pivotal role in physician education, providing hands-on experience with the Focal One system, and fostering peer-to-peer knowledge sharing as experienced users share their clinical insights and expertise. We believe sustained investment in physician education remains one of the most effective ways to build lasting scalable adoption of focal therapy.
Turning to expanding clinical indications on the Focal One platform, we continue to advance our BPH clinical program, building on the active study in Chile, which we are conducting with urologists from the Icahn School of Medicine at Mount Sinai in New York. This important work remains ongoing, demonstrating early encouraging results. We remain positive on the large opportunity to use Focal One as a non-invasive, bloodless procedure for the treatment of BPH, and we look forward to updating you as our program progresses. We continue to make encouraging progress in expanding the use of Focal One for the treatment of deep infiltrating endometriosis, with three centers in Europe now treating commercial patients. These include two sites in France, along with one in Hungary. This momentum reflects the positive impact of our dedicated CE mark, supported by a growing body of clinical evidence.
Beyond these three centers, multiple physicians from other centers across Europe, including the U.K. and France, are going through the training pathway so they can offer this treatment to their endometriosis patients locally. Our focus is to expand selectively, adding key centers as we build on this limited launch. Finally, in September, we were honored to be awarded the Innovation Champion Award at the European Investment Bank TechEU Equity Summit in Luxembourg. We believe this recognition as a reflection of the significant progress we are making at FocalTherics to define, build, and lead the category of robotic focal therapy. We believe the third quarter reinforces the growing demand for Focal One across both established and new markets and the depth of commitment we see from leading healthcare systems to select Focal One as the foundational technology platform of their focal therapy programs.
As referenced, we are making continued progress in expanding reimbursement both in France with universal coverage and in the U.S. with commercial payer coverage for salvage treatments. With that, I will now turn it over to Ken to review the financials in more detail.
Ken? Thanks, Ryan, and good afternoon, everyone.
As a reminder, this is our second quarter presenting our financial results under our revised reporting structure, in which our HIFU business is presented as continued operations and our ESWL and distribution businesses are presented as discontinued operations. All prior period comparisons have been recast on this basis, and the recast financials are available in our Form 8-K, which is posted on our website and can also be found on the SEC's website. We believe the structure allows investors to evaluate our HIFU business on its own terms, including its growth rate, margin profile, and the level of investment required to support it. Unless otherwise noted, my commentary refers to our HIFU segment. Revenue for the third quarter was $9.8 million, an increase of 26% compared to $7.8 million in the third quarter of 2025.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
6 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
